Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions (Emergent) has completed the acquisition of Trubion Pharmaceuticals (Trubion) following a majority vote from the Trubion stockholders.
Subscribe to our email newsletter
With this take over, Emergent gains access to multiple, advanced stage candidates in the key disease areas of oncology and autoimmunity as well as access to new and versatile protein therapeutic platforms.
Emergent chairman and CEO Fuad El-Hibri said that Emergent’s acquisition of Trubion helps achieve their goal of diversifying beyond infectious diseases.
Emergent said that it will maintain research facilities in Seattle, Washington and the location will become a therapeutics-focused product development site.